Chorioallantoic Membrane Vascular Assay (CAMVA)
Alternative Ocular Irritation Test
Developed as an alternative in ovo toxicity assay to the Draize Rabbit Eye Test. Similar to the HET-CAM, the CAMVA uses the vascularized membrane of fertile chicken eggs to assess
a test material's potential to cause vascular changes (hemorraghing, capillary injection, ghost vessels).
Alternative toxicity assay to Draize Rabbit Eye test
Uses the vascularized chorioallantoic membrane of fertile chicken eggs
High concordance to in vivo data
Topical Dosing: Liquids and Solids
Rapid and Cost-Effective Alternative
Effective Ocular Irritation Screening Test for Cosmetics and Pharmaceutical Products
Damage to the vascular structure (i.e. ghost vessels, capillary injection, and/or hemorrhaging) of the chorioallantoic membrane (CAM) of fertilized chicken eggs is assessed after topical exposure of a test chemical which is then used as an endpoint to determine the potential for conjunctival irritancy.
CAMVA can be used to investigate the vascular effects such as neovascularization, angiogenesis, and anti-angiogenesis, which are of particular interest to pharmaceutical and cosmetic product research and development.
Assessment of the chorioallantoic membrane vascular assay (CAMVA) in the COLIPA in vitro eye irritation validation study. Toxicol In Vitro. 1999 Apr;13(2):285-93.
Bagley DM, Cerven D, Harbell J.
Survey of ocular irritation predictive capacity using Chorioallantoic Membrane Vascular Assay (CAMVA) and Bovine Corneal Opacity and Permeability (BCOP) test historical data for 319 personal care products over fourteen years. Toxicol In Vitro. 2011 Mar;25(2):563-72. Epub 2010 Dec 13.
Donahue DA, Kaufman LE, Avalos J, Simion FA, Cerven DR.
The CAMVA is similar to the European HET-CAM, where damage to the vascular structure of the
chorioallantoic membrane (CAM) of 10-day-old fertilized chicken eggs is assessed after topical
exposure of a test chemical. Vascular responses are observed, scored and used as an endpoint
to determine the potential for conjunctival irritancy. CAMVA is also used to investigate
vascular effects such as neo-vascularization, angiogenesis, and anti-angiogenesis, which are
of particular interest to pharmaceutical and cosmetic product research and development.
MB Research personnel have been involved in the development and marketability of alternative
assays since 1988 when, with the help of personnel from Colgate-Palmolive, the CAMVA was
developed and validated at MB Research Laboratories. Current CAMVA protocols are based
upon methodology described in An Improved CAM Method for Predicting Ocular Irritation
Other Ocular Irritation Assays